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Abstract (249):
Background: Asthma is a complex disease with multiple phenotypes that may differ in disease pathobiology and treatment
response. Interleukin 33 (IL33) single nucleotide polymorphisms (SNPs) have been reproducibly associated with asthma. IL33
levels are elevated in sputum, and bronchial biopsies of asthma patients. The functional consequences of IL33 asthma SNPs
remain unknown.
Objective: We studied whether IL33 SNPs associate with asthma-related phenotypes and with IL33 expression in lung or
bronchial epithelium. We investigated the effect of increased IL33 expression on human bronchial epithelial cell (HBEC)
function.
Methods: Association between IL33 SNPs ( ) and asthma phenotypes (Lifelines/DAG/GASP
cohorts) and between SNPs and expression (lung tissue, bronchial brushes, HBECs) was done using regression modelling.
Lentiviral overexpression was used to study IL33 effects on HBECs.
Results: 161 SNPs spanning the IL33 region associated with one or more asthma phenotypes after correction for multiple
testing. We report one main independent signal tagged by rs992969 associating with blood eosinophil levels, asthma and
eosinophilic asthma. A second, independent signal tagged by rs4008366 presented modest association with eosinophilic
asthma. Neither signal associated with FEV1, FEV1/FVC, atopy, and age of asthma onset. The two IL33 signals are expression
quantitative loci (eQTLs) in bronchial brushes and cultured HBECs, but not in lung tissue. IL33 overexpression in vitro resulted
in reduced viability and ROS-capturing of HBECs, without influencing epithelial cell count, metabolic activity or barrier
function.
Conclusion: We identify IL33 as an epithelial susceptibility gene for eosinophilia and asthma, provide mechanistic insight, and
implicate targeting of the IL33 pathway specifically in eosinophilic asthma.
Key Messages:
- Genetic signals at the IL33 locus predominantly associate with blood eosinophil counts in the general population and
with an eosinophilic asthma phenotype.
- These genetic signals influence IL33 levels in the airway epithelium, with the disease risk allele associating with
elevated IL33 in vivo.
- Elevated IL33 has modest paracrine effects on bronchial epithelial cell function in vitro, implicating that epithelial
derived IL33 may more likely affect other effector cell types such as type 2 immune cells, eosinophils or mast cells.
Capsule Summary (30, max 35 words):
This study identifies IL33 as an epithelial susceptibility gene for eosinophilia and eosinophilic asthma, supporting the IL33
pathway as a likely candidate for targeted treatment strategies specifically in eosinophilic asthma.
Keywords:
asthma phenotypes, IL33 SNPs, eQTL, bronchial epithelium, functional translation
Abbreviations:
AHBEC: Asthma Human Bronchial Epithelial Cell
ALI: Air Liquid Interface
AOO: Age Of Onset
AUC: Area Under the Curve
BEGM: Bronchial Epithelial Growth Medium
BHR: Bronchial Hyper Responsiveness
CMV: CytoMegaloVirus
ECIS: Electric Cell Substrate Impedance Sensing
EUR: European
DAG: Dutch Asthma GWAS
FDR: False Discovery Rate
FeNO: Fraction of exhaled Nitric Oxide
FEV1: Forced Expiratory Volume 1st second
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GASP: Genetics of Severe Asthma Phenotypes
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ROS: Reactive Oxygen Species
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SNP: Single Nucleotide Polymorphism
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Introduction:
Asthma is a common, complex, heterogeneous disease that results from the interaction between genetic
and environmental factors. It is a chronic inflammatory condition of the airways, characterized by bronchial
hyperresponsiveness and reversible airway obstruction. Asthma may consist of several endotypes characterized by
differences in specific phenotypes, underlying pathobiology, and (treatment) outcomes in individual patients(1).
Genome-wide association studies (GWAS) have identified a large number of asthma loci(2-9), including single
nucleotide polymorphisms (SNPs) in Interleukin (IL)33 and the gene encoding its receptor Interleukin 1 Receptor
Like 1 (IL1RL1)(9). Both loci were originally discovered as associated with blood eosinophils in general population
cohorts(10,11). Next to these common SNPs, a rare IL33 loss of function mutation has been shown to reduce blood
eosinophil counts and protect from asthma(12).
IL33 is an alarmin released upon cellular damage from e.g. epithelial cells. Extracellular IL33 induces
signalling via the heterodimeric receptor complex IL1RL1/IL1RAP. Airway IL33 levels have been associated with
type 2 cytokines levels and a positive correlation with eosinophil numbers in asthma patients was recently
reported(13). High IL33 levels have been found in induced sputum and bronchial biopsies of asthma patients
compared to non-asthmatic controls(14-16). Moreover, IL33 may have a paracrine effect on the airway epithelium,
as this epithelium has been shown responsive to IL33(17,18). These data suggest a connection between epithelium-
derived IL33, eosinophilic inflammation and asthma.
Nevertheless, the functional relevance of common asthma-associated SNPs in IL33 remains largely
unknown. Moreover, genetic association studies thus far have focused on asthma diagnosis, while the contribution
of genetic variants to distinct phenotypes of asthma has not been addressed. We hypothesize that genetic variants
at the IL33 locus drive specific phenotypes of asthma by activating a type-2 cytokine dominated immune response,
characterized by eosinophilic lung inflammation. Therefore, this study aimed to investigate 1) whether SNPs in
the IL33 region associate with specific asthma phenotypes; 2) whether these IL33 SNPs form quantitative trait loci
(QTL) for IL33 expression in lung tissue and/or bronchial epithelial samples in vivo and in vitro; and 3) whether
increased IL33 expression alters human bronchial epithelial cell function.
Materials/Methods:
Detailed methods are described in the online supplement.
Codes available on https://git.web.rug.nl/P252222/IL33_Ketelaaretal_JACI2020.
Study design (see also figure 1)
SNPs in the region of IL33 were tested for association with asthma
phenotypes using regression modelling. Briefly, we tested association of the IL33 SNPs in a Dutch general
population cohort (Lifelines(19); n=13,395) with eosinophil counts, FEV1 and FEV1/FVC. From this general
population cohort we subsequently took the asthma subpopulation (n=1, and
investigated genetic association with eosinophil counts, eosinophilic asthma (asthma and blood eosinophils >150
cells/µL, n=707, as this cut-off is a good predictor for airway eosinophilia (>2% sputum eos (20), non-eosinophilic
asthma (asthma and blood eosinophils <150 cells/uL, n=359), FEV1, FEV1/FVC and asthma with airway
obstruction (asthma and FEV1<80% of predicted (n=258) or FEV1/FVC<70% (n=324)). In a meta-analysis of two
independent asthma cohorts of n=2,536 moderate-severe asthma patients (GASP, UK(21))) and n=909 asthma
patients of mild-moderate severity (DAG, the Netherlands(22)), we then evaluated association of IL33 SNPs with
atopy, blood eosinophils, total serum IgE, age of asthma onset, and lung function (FEV1, FEV1/FVC).
We then selected independent genetic signals based on LD (r2<0.1), followed by conditional analyses on the most
significantly associated SNP. Functional investigations of selected independent genetic signals included
expression and protein quantitative loci studies in lung tissue (n=1,111), bronchial brushes (n=139) and primary
asthma derived human bronchial epithelial cells (AHBECs, n=35). Potential function was investigated using
ENCODE, PredictSNP, Meta-SNP, and Polyphen-2 data(23-25). We tested for inducible expression (e)QTL and
protein (p)QTL by exposing AHBECs (n=18) of various IL33 genotypes to asthma-relevant stimuli (HDM, RV16).
Finally, we overexpressed IL33 in (healthy-derived) HBECs (n=5) to investigate effects on cell count, metabolic
activity, viability, ROS-capturing and epithelial barrier.
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Genotype-phenotype analysis
A total of 1,970 imputed SNPs (Lifelines, all overlapping with DAG/GASP) and 2,457 imputed SNPs
(DAG/GASP) were available for the association analyses based on and chromosomal location of
400kb up- and downstream IL33 (Chr9: . This region encompasses all known asthma-
associated SNPs (table I, table S1). Associations of SNPs with asthma phenotypes were performed with PLINK
v1.90b6.7(26) (Lifelines (27) (DAG/GASP) using an additive genetic model. DAG/GASP were
meta-analysed in METAL(28) using a fixed model, (table S2-S3). An adjusted p-value (P.adj)<0.05 (FDR) was
considered statistically significant.
Functional genetics
QTL and ENCODE investigations
We tested for expression quantitative trait loci (eQTL) in lung tissue (n=1,111) and bronchial brushes (n=139)
(table S5) using a linear regression model to investigate the association between SNPs and log-transformed IL33
expression data. We employed an additive genetic model with age, gender, smoking status and the PCs explaining
>1% of expression variance as covariates using R statistics(29). We did not have data on medication use for these
cohorts, so could not correct for this covariate, but the currently used covariates are thought to reflect main
confounders in eQTL analyses (22,30).We also tested for (inducible) QTLs in cultured bronchial epithelial cells
(n=18-35) obtained from bronchial brushes/biopsies from asthma patients as described(31). AHBECs were
stimulated with 50µg/ml house dust mite (HDM) or rhinovirus (RV16, MOI=1) for 24 hours and RNA lysates
collected(32). Cells were genotype-stratified and expression compared using Kruskal-Wallis tests. A p-value<0.05
was considered statistically significant. ENCODE was used to identify potential functional effects of tagSNPs and
SNPs in LD (r2>0.3). SNPs were functionally checked for DNase I hypersensitive sites, histone mark sites, binding
motifs, and regulatory motifs using RegulomeDB, HaploReg, ChromHMM and Segway(23,24).
Functional bronchial epithelial cell studies
In order to investigate the functional consequences of increased IL33 in bronchial epithelial cells, we stably
overexpressed human full-length IL33 (aa1-270) in primary HBECs isolated from 5 healthy individuals (Lonza,
#CC-2540). IL33 mRNA and protein expression was quantified by qPCR and immunofluorescence respectively.
We analysed cell count, viability and metabolic activity, as well as ROS-capturing ability (glutathione assay) and
barrier function (ECIS) in these cultures. We used Kruskal-Wallis for all parameters except for longitudinal area
under the curves (AUCs) comparisons of ECIS data, which were compared using a Z-test. A p-value<0.05 was
considered statistically significant.
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Results:
Genetic association with phenotypes of asthma:
The IL33 locus particularly associates with eosinophilia and eosinophilic asthma
Overall in DAG/GASP and Lifelines (S2-S3), 161 SNPs significantly associated with one or more asthma
phenotypes (P.adj<0.05 (FDR); tables S11-15), mainly derived from the Lifelines cohort. From these, 144 SNPs
comprised five LD blocks (A-E, r2>0.1). Markedly, these five LD blocks all associated with an eosinophilic
phenotype; either with blood eosinophil counts, eosinophilic asthma and/or asthma (table I, tables S11-S17, figure
E2/E3). LD block A shows a significant association with blood eosinophil counts in the general population
(tagSNP rs992969[allele A] beta=0.058+/- SE=0.0089, P.adj=7.09E-08, AF=0.25), whilst three other LD blocks
were modestly associated with this phenotype (block B-D, table I). Block E showed association with eosinophilic
asthma (tagSNP rs4008366 [allele T], OR=1.26+/-SE=0.0704, P.adj=0.045, AF=0.67) only.
Outside these five LD blocks, seven SNPs significantly associated with other phenotypes (age of onset or
FEV1/FVC, table S15) and ten significant SNPs were identified in the case-control analyses of resequencing data;
these were relatively rare (MAF~0.03, table S17) and hence were not followed-up functionally. We performed
conditional analyses on the LD blocks associated with eosinophilic phenotypes to determine independent signals.
A summary description of association results can be found in the supplementary section M1.
Conditional and sensitivity analyses show one main genetic signal associated with blood eosinophil counts in the
general population
Four LD blocks (A-D, figure 2) showed association with blood eosinophil counts in the Lifelines general
population. Thereby, block A (tagSNP rs992969) shows the largest effect size and statistical significance (table I);
rs992969 explaining 1.6% (R2 regression model=0.016) of the variance in blood eosinophil counts (corrected for
age/gender). Therefore, we conditioned the association analysis for blood eosinophils on rs992969 to test whether
block A-D are independent signals. Conditioning removed the association of signals B-D with blood eosinophil
counts in the general population (see figure 3 and table II). Signal E was not significantly associated with
eosinophil counts, regardless of conditioning. Sensitivity analysis for the main signal A showed that rs992969 still
associated with eosinophil counts in the general population when removing asthma patients (figure 3a-2)
(n=12,329; rs992969 [allele A] beta=0.055, SE=0.009, R2=0.017, P.adj=1.04E-06) or both asthma/allergic patients
(figure 3a-3) (n=6,227; rs992969 [allele A] beta=0.046, SE=0.012, R2=0.020, P.adj=0.02). These analyses show
the presence of one main genetic signal (A) at the IL33 locus associated with blood eosinophil counts in the general
population, independent of the presence of asthma/allergy phenotypes.
Signal A and E associate with eosinophilic asthma
Signal A, driving the association with blood eosinophil counts in the general population, also showed a significant
association with asthma (rs992969[allele A], OR=1.22, SE=0.05, P.adj=0.03) and with eosinophilic asthma
(rs992969[allele A], OR= 1.32+/-SE=0.0618, P.adj=4.73E-03), (figure 3+4). Signal A contains several SNPs
previously associated with asthma (table I). The genetic effect of this main signal on asthma risk remained of
similar size, even when correcting for blood eosinophil counts (OR[A] from 1.22 (P.adj=0.03) to 1.19 (P.adj=0.08),
figure 4b).
Signal E was the other LD block associated with eosinophilic asthma (tagSNP rs4008366, figure 4d), with a
significantly large effect size. Lack of power precluded conditional analyses for the eosinophilic asthma
phenotype, so (in)dependency of block E could not be confirmed. However, this block represents a genetically
independent signal in other cohorts (table II), underscoring it may be a distinct signal and may represent a distinct
mechanism underlying asthma pathogenesis. Therefore, two signals (A and E) were selected for functional follow-
up.
To assess whether our definition of eosinophilic asthma based on the cut-off for blood eosinophils at 150 cells/uL
impacted on the associations observed, we repeated the analysis at a cut-off of 300 cells/uL as a definition for
eosinophilic asthma. These additional analyses of eosinophilic asthma, including a higher cut-off of eosinophil
counts, identify the same associations with slightly higher effect sizes (see supplemental table S8/S9), but not FDR
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Table II- Conditioning on rs992969 in the association of IL33 with blood eosinophils in the general
population of Lifelines removed signals B-D
Conditional analyses were performed in n=13,395 subjects from the Lifelines general population, studying the
effect of IL33 SNPs on level of blood eosinophils, by taking rs992969 (=lowest p-value SNP associated with
level of blood eos) as covariate in the regression model. These were put into the context of independent SNPs as
determined in other large cohorts. r2= relative to tagSNP of LD block A/B/C/D/E respectively.
* Signal E was not significantly associated with level of blood eosinophils in the general population before
conditional analyses, nor after conditional analyses, but has only been included in this table to show it is in
modest LD with rs343478 (an independent signal in other studies). Because of its association with eosinophilic
asthma, lack of LD with signal A, as well as this LD block also represented an independent signal in multiple
studies, we took this signal forward as an independent phenotype-associated signal in our functional analyses.
**In bold the unconditioned results, in italics the results conditioned on rs992969.
***Adjusted p-value (FDR) statistically significant <0.05.
^ Independent phenotype-associated SNPs at the IL33 locus determined based on conditional analyses in other
large population cohorts: the phenotype studied in the UK Biobank/INTERVAL was blood eosinophil levels in
the general population (n=173,480)(10), in the UK biobank only was asthma (n=41,926 cases vs. n=239,773
controls) (36), whilst the SHARE study examined a combined asthma/allergy phenotype (n=180,129 cases vs
180,709 controls)(37).
Underlined: the two genetic signals taken forward in functional assessment in this study
Translating IL33 genetics in asthma- Ketelaar, Portelli, Dijk et al
QTL/functional investigation of IL33 genetic variation:
After conditional analyses, two independent signals A and E remained for functional follow-up, each with a
tagSNP (rs992969 and rs4008366, table II). These tagSNPs were chosen based on smallest p-value/largest effect
size, largest number of associated phenotypes and if applicable known association with asthma from literature. In
case the tagSNP was not available for functional look-up, a proxySNP at r2>0.5 with the tagSNP of the original
association signal was chosen (table S7).
Signal A and E are IL33 eQTL in bronchial epithelium
To investigate potential functionality of signal A and E, QTL analyses were performed in lung tissue, bronchial
epithelial brushes and cultured bronchial epithelial cells (see table III, S5 and figure 5).
In lung tissue samples, no eQTLs for IL33 were found (table S19 and figure E4). In bronchial brushes, the tagSNP
of signal A was a significant and strong eQTL for IL33, with the disease associated allele correlating with higher
mRNA levels, (rs992969[A] beta=0.331, SD=0.043, P=8.30E-12, AF=0.25). No significant eQTLs were found
for signal E in bronchial brushes. In cultured primary human bronchial epithelial cells (HBECs), the disease
associated allele of signal E (proxy SNP rs442246) associated with lower IL33 mRNA (P=0.029, see table III and
figure E6b). No significant pQTLs were found for IL33 in HBECs for both signal A and E (figure E7).
Signal A and E harbour potential functional elements related to expression regulation of IL33
ENCODE revealed several putative regulatory elements for SNPs in both genetic signals A and E relevant for IL33
transcription (table IIIb). Signal A contained 27 SNPs (LD r2>0.3 with tagSNP) with potential functionality.
Among these is a SNP (rs928413) in strong LD with the phenotype and expression associated tagSNP rs992969
(r2=0.96), forming a CREB1 binding site activating the IL33 promotor. In signal E, 7 SNPs were potential
functional elements, including specific transcription factor binding sites relevant to the regulation of the cellular
oxidative state (e.g. Nrf2) in lung derived cells. Thus, the genetic signals A and E contain likely functional elements
related to expression, forming a potential mechanistic link between phenotype and expression association.
Asthma stimuli induce differential IL33 expression, regardless of genetic background for signal A and E
Next, we tested for the presence of inducible QTLs for IL33 in primary AHBECs after exposure to RV16 (MOI:1)
or house dust mite (HDM, 50µg/mL) and analysed for effects on IL33 mRNA and extracellular protein levels in
an unstratified way or stratified for genetic signals A and E. RV16 induced a decrease in IL33 mRNA levels in
AHBEC (P=0.048), and a marked increase of IL33 protein in the cellular supernatant (P=0.0001). HDM exposure
induced an increase in IL33 RNA and had no significant effects on IL33 protein levels, measured 24h post
stimulation (figure E7). When stratified on signals A and E, no significant differences on the RV16 or HDM
induced effects on IL33 mRNA or protein levels were observed (figures E8/E9).
IL33 overexpression modestly impairs bronchial epithelial cell homeostasis:
In order to investigate the effect of increased IL33 expression, we overexpressed full length IL33 in primary
bronchial epithelial cells using lentiviral delivery (figure E11/E12). We confirmed increased expression of IL33 at
the mRNA level and presence of IL33 protein in engineered cells (figure 5 and figures E13/E14). We found that
overexpression of IL33 does not significantly influence cell number or metabolic activity (figure E15). Viability
was 15-20% lower (P=0.04, figure 5c) and ROS-capturing capacity (presence of free glutathione) was ~20% lower
(P=0.03, figure 5d) in cells that overexpressed IL33 under submerged culture condition. No effect of IL33
overexpression was seen on spreading or formation of an epithelial barrier using ECIS (figure E14).
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Discussion
We set out to determine if SNPs in the IL33 region associate with specific phenotypes of asthma, whether these
regulate IL33 expression in lung tissue or bronchial epithelial samples, and whether increased IL33 expression
alters human bronchial epithelial cell biology. Genetic signals at the IL33 locus predominantly associate with an
eosinophilic phenotype in the general population and asthma subjects, whereby the IL33 risk allele is associated
with higher IL33 expression in vivo. Using conditional analyses we observed one major genetic signal and one
secondary signal. The major signal associates with blood eosinophil counts and (eosinophilic) asthma, while the
secondary signal associates with eosinophilic asthma but not with eosinophil counts in the general population.
Importantly, no association with other asthma-related phenotypes including lung function, atopy, serum IgE levels
and asthma age of onset was observed. Studying the effects of these two genetic signals on IL33 transcription, we
report eQTLs in bronchial brushes and cultured bronchial epithelial cells, but not in lung tissue. Overexpression
of IL33 in bronchial epithelial cells resulted in modest paracrine effect on epithelial cell homeostasis, including
reduction in cell viability and ROS-capturing capacity. With this approach we identify IL33 as an epithelial
susceptibility gene for eosinophilia and asthma, provide mechanistic insight, and support targeting of the IL33
pathway specifically in eosinophilic asthma.
Two genetic IL33 signals associate with eosinophilia in health and disease
The IL33 gene, and the IL1RL1 gene encoding its receptor, have consistently been associated with asthma and
allergy(3-8,21,33-37). Both loci were originally discovered as regions associating with blood eosinophils in the
Icelandic population(11,33), and a strong association with blood eosinophil counts was recently confirmed in a
large general population cohort (n=173,480), combining UK Biobank and INTERVAL studies(10). Also, a rare
loss-of-function IL33 mutation was shown to both reduce eosinophil counts and to protect from asthma(12). These
observations suggest a shared genetic effect of this locus for eosinophilia and asthma. However, it remained
unknown whether these are the same or distinct genetic signals and what additional asthma related phenotypes
these signals may be associated with.
We report five LD blocks that were associated with either blood eosinophil counts and/or eosinophilic
asthma, which after conditional analysis correcting for the strongest signal (rs992969), were reduced to two
independent signals. The fifth signal (E) was not associated with blood eosinophil counts in the general population,
but with eosinophilic asthma. The available subjects (n=707) for the eosinophilic asthma phenotype did not allow
conditional analyses for signal E. However, previous analyses in two very large cohorts (SHARE(37) and UK-
biobank(36) supported the independence of signal E, representing a second signal associated with an eosinophilic
phenotype in our cohorts. This left us with two genetic signals for further study.
We observe a strong association for signal A with both asthma and blood eosinophil counts in our
Lifelines general population cohort, the tagSNP rs992969 explaining 1.6% (R2=0.016) of the variance in
eosinophil counts (corrected for age/gender). SNPs within this signal have previously been reported to associate
with asthma in the UK Biobank, SHARE, and TAGC study, as well as in earlier asthma meta-
analyses(2,4,5,7,21,35-37) and with blood eosinophil counts in the UK biobank/INTERVAL study (rs992969 in
LD r2=0.95 with rs2381416 from UK Biobank/INTERVAL)(10). Using a sensitivity analysis in Lifelines by
removing asthmatic and allergic subjects from the general population, we show that the association with blood
eosinophils remained present with a similar effect size, indicating that the association between this signal A and
blood eosinophils is not fully driven by the presence of asthma or allergy. We find that the association of signal A
with asthma is of similar effect size when correcting for blood eosinophil counts, suggesting that this IL33 genetic
signal- in addition to its effect on blood eosinophil counts- may have an effect on asthma. However, we do find
that the effect of signal A on asthma after correcting for blood eosinophils is no longer FDR significant. (Figure
4.) Therefore, a better powered study is required to conclusively investigate an effect of this signal on asthma
independent from eosinophil counts. Interestingly, we observed an association of signal A with eosinophilic
asthma, but not with non-eosinophilic asthma (figure 4), indicating that patients with this IL33 genetic make-up
would be enriched in the high-eosinophil group. A note of caution is the relatively limited number of subjects in
our non-eosinophilic asthma group (n=359).
An intriguing implication could be that in asthma patients with this particular genetic background (signal A),
treatment targeting the IL33 pathway could have additional effects over treatments targeting eosinophils(42,43).
Notwithstanding, whether the association of IL33 SNPs with asthma and eosinophils are (in)dependent from each
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other remains to be conclusively determined in larger cohorts, allowing causal inference/mediating approaches
like Mendelian randomization(44). Ideally, such an analysis would also take into account IL1RL1 genotypes,
which are likely to interact with IL33 variants on outcomes such as eosinophilic inflammation; as well as a more
direct measure of eosinophilic airway inflammation such as sputum eosinophil counts should be considered.
Functional effects of phenotype-associated IL33 polymorphisms and IL33 expression
Functionally, IL33 signalling has previously been linked to Th2-driven inflammation, contributing to eosinophilic
inflammation(45-47). Moreover, levels of IL33 have been found elevated in induced sputum and bronchial
biopsies of asthma patients compared to non-asthmatic controls(14-16), indicating a dysregulation of IL33
homeostasis in asthma. Therefore, specific genetic variation at the IL33 locus might contribute to eosinophil
numbers and asthma through regulation of IL33 expression levels.
While we did not detect eQTLs for IL33 in lung tissue samples, the tagSNP of signal A was a strong
eQTL for IL33 in bronchial epithelial brushes from healthy subjects (table III, figure 5), with the risk allele
associating with increased IL33 mRNA levels. Signal A harbours a reported IL33 eQTL in a candidate eQTL study
of bronchial biopsies(30), with the same direction of effect. This eQTL signal A also comprised a SNP (rs928413,
in LD r2=0.96 with rs992969) where the phenotype-risk allele was recently found to form a CREB1 binding site,
functionally activating the IL33 promotor in lung epithelial cells(41). This allele associates with higher level of
eosinophils, higher risk of (eosinophilic) asthma and increased IL33 expression in brushes in our cohorts. As lung
tissue resection samples mainly consist of parenchymal lung tissue with minor contributions of airway epithelial
cells, while bronchial brushes contain more than 90% bronchial epithelial cells(48), we interpret these data as
evidence for regulation of IL33 expression in bronchial epithelium.
The bronchial epithelium is the first barrier that the inhaled substances encounter when entering the lung,
and serves to protect the body from potential threats from the environment. The airway epithelium is changed in
asthma patients, with increased susceptibility to and altered repair responses after external damage(49,50), for
example in response to respiratory viruses(51). A GWAS on exacerbation in asthma(2) found the IL33 locus
associated with frequent virus-induced exacerbations in severe childhood-onset asthma, their main IL33 SNP in
strong LD (r2=0.96) with our eosinophilic signal rs992969. Therefore, we tested whether our two phenotype-
associated signals are baseline and/or induced QTLs in cultured bronchial epithelium. Signal E is a modest,
baseline IL33 eQTL, with the eosinophilic risk allele associated with lower IL33 mRNA levels (table III) in these
cells. Although both RV16 and HDM regulated IL33 expression, no effect of the two IL33 signals on the RV16
and HDM induced IL33 response was observed in vitro in our samples. This could indicate that our two signals
may specifically have effects on baseline changes of IL33 expression in epithelium.
The opposite direction of effect in the cultured bronchial epithelial cells compared to the bronchial brushes might
indicate that IL33 gene regulation is different in asthmatic epithelium compared to healthy brushed cells, in
agreement with recent data from Jurak et al. (2018)(52). Alternatively, it could reflect differences in epithelial
cell state with cultured HBECs having a basal cell phenotype(48,53), while bronchial brushes contain mostly
well-differentiated ciliated and secretory epithelial cells(48).
The cell-autonomous effects of increased IL33 expression on cultured HBECs were modest. Nevertheless, the
observed effect of sustained IL33 on reduction of glutathione levels in the epithelium is interesting, as Uchida et
al.(18) showed that the balance between oxidative stress and antioxidant responses plays a key role in controlling
IL33 release from airway epithelium. Our data indicate that the bronchial epithelium is the source of IL33, but
that other cell types should be considered as the main IL33 responsive population, such as tissue-resident
dendritic cells, eosinophils, type 2 innate lymphoid cells, Th2 cells, mast cells and basophils, but also lung
mesenchymal, such as fibroblasts. This is also relevant in the context of steroid-resistant asthma patients. For
example: elevated IL-33 and type 2 cells were still present in corticosteroid resistant pediatric asthma patients,
contributing to airway remodelling via its effects on airway fibroblast.(54,55)
In conclusion, we have reduced the complex IL33 locus into one major and one secondary genetic signal for
eosinophilic asthma. The major IL33 signal risk allele associates with increased IL33 expression levels providing
a putative mechanism. Importantly we have also shown a lack of genetic association of this main genetic signal
with other studied asthma phenotypes. We identified the bronchial epithelial cell as the likely cellular source of
IL33 QTL signals, which is crucial to place the genetic effects on IL33 expression in asthma pathophysiology.
These data need confirmation by e.g. single-cell eQTL analyses in airway wall samples of asthma patients and
healthy controls. This approach might also guide the identification of the main IL33 responding cells.
Nevertheless, our data identifies IL33 as an epithelial susceptibility gene for eosinophilia and asthma, and
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supports the IL33 pathway as a likely candidate for targeted treatment strategies in specifically eosinophilic
asthma, with the potential to affect both eosinophil counts and asthma independently.
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Figure 1: Overview of the flow of the analyses
In above figure the flow of analysis of the current paper is shown. In the first phase, SNPs in a candidate region (400kb+/-
IL33) were associated with asthma phenotypes in Lifelines (n=13,395) and GASP/DAG cohorts (1), including blood
eosinophils, blood neutrophils, FEV1, FEV1/FVC, atopy, blood IgE and age of asthma onset. A total of 161 SNPs
(MAF>0.01) were associated with one or more of these phenotypes; the majority of these associations were found in the
Lifelines general population cohort. A total of 5 independent LD blocks (r2>0.1) were identified (2a). Conditional analyses
on the most significantly associated SNP revealed 2 independent signals left for functional study in QTL cohorts (2b). eQTLs
were studied in lung tissue (n=1,111) and bronchial brushes (n=139), eQTL and pQTL in cultured primary human bronchial
epithelial cells (HBECS, n=35 (3)). Then, functional elements in the phenotype-associated genetic signals were investigated
using ENCODE, PredictSNP, Meta-SNP, Polyphen-2 data (4). Further functional study was done by exposing HBECs (n=18)
to asthma-relevant stimuli (HDM, RV16), investigating inducible eQTL and pQTL; as well as investigating the functional
effects of elevated IL33 (n=5) in vitro, including cell count, metabolic activity, viability, ROS-capturing and resistance (5).
Figure 2- The LD pattern of the five LD blocks (r2>0.1) with phenotype association
The panel shows the LD pattern of the 5 LD blocks/signals (r2>0.1) from the 144 SNPs significantly (FDR<0.05) associated
with asthma features in the Lifelines general population, Lifelines asthma population and DAG/GASP asthma population.
Signal A and E were taken forward in functional assesment in this study. Image generated using the EUR population of the
Phase I cohort of the 1000 genomes study via the online software tool LDlink 3.0, available at:
https://analysistools.nci.nih.gov/LDlink/?tab=home.
Figure 3- Conditioning on the main genetic eosinophilic signal A (rs992969) removes three other signals
(B,C,D) associated with blood eosinophils in the general population of Lifelines.
In figure 3 the association between IL33 region SNPs and level of blood eosinophils in the general population is
shown. Four LD blocks (r2>0.1) could be distinguished for this phenotype (LD block A-D), with LD Block A
representing a strong signal, and block B-D a modest signal. Indeed, conditioning on the tagSNP of LD block A
(rs992969) removed signals B-D. Conditional analyses were performed in n=13,395 subjects from the Lifelines
general population, studying the effect of IL33 SNPs on level of blood eosinophils, by taking rs992969 (=lowest
p-value SNP associated with level of blood eos) as covariate in the regression model. Statistical details can be
found in table II. Red line indicates the cut-off at which the adjusted p-value (FDR) is 0.05. Plots generated
using LocusZoom.(38)
Figure 4- The main genetic IL33 signal (signal A) selected for functional follow-up associates with level of
blood eosinophils (a), asthma diagnosis (b) and eosinophilic asthma (c), whilst signal E associates with
eosinophilic asthma (d)
Fig 4a- Signal A (tagSNP rs992969) associates with level of blood eosinophils in the general population of
Lifelines (a1), independent of the presence of asthma/allergy (a2 and a3). In panel a1 the results of the
association between IL33 SNPs and blood eosinophil levels in the total general population (n=13,395) of
Lifelines are shown, the reference SNP (purple) indicating the tagSNP of LD block A: rs992969, which was
significantly associated with blood eosinophil (beta [A allele]= 0.058, SE=0.009, P.adj=7.09E-08). In panel a2
this association was performed in the general population lacking asthma (n=1,066 asthma patients removed),
rs992969 (purple) still associating with blood eosinophil levels at similar effect size (n=12,329; rs992969 [A]
beta=0.055, SE=0.009, P.adj=1.04E-06). In panel a3 individuals with asthma and allergies (n=6,227
asthma/allergic subjects) were removed, and also then rs992969 (purple dot) associated with blood eosinophil
levels at similar effect size (n=7,168; rs992969 [A] beta=0.046, SE=0.012, P.adj=0.02). Red line indicates the
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cut-off at which the adjusted p-value (FDR) is 0.05. Asthma was defined as self-reported doctor-diagnosed
asthma. Allergy was defined based on at least one self-reported allergy, including eczema, rhinitis, food allergy,
dust allergy, animal allergy, pollen allergy, medication allergy, contact allergy, and insect bite allergy. Plots
generated using LocusZoom.(38)
Fig 4b- Signal A (tagSNP rs992969) associates with asthma diagnosis (Lifelines). Here the association
between IL33 locus SNPs and all asthma is shown, with panel b1 showing the association model corrected for
age and gender, whilst in panel b2 the model in addition was corrected for level of blood eosinophils. b1- All
asthma, uncorrected for blood eosinophils; asthma patients (n=1,066) vs healthy controls (n=6,863) (rs992969
[A], OR= 1.22, SE= 0.05, P.adj=0.03); b2- All asthma, corrected for blood eosinophils; asthma patients
(n=1,066) vs healthy controls (n=6,863) (rs992969 [A], OR=1.19, SE= 0.05, P.adj=0.08). Red line indicates the
cut-off at which the adjusted p-value (FDR) is 0.05. Plots generated using LocusZoom.(38)
Fig 4c- Signal A (tagSNP rs992969) also associates with eosinophilic asthma in Lifelines (c1), but this
signal is not present in non-eosinophilic asthma (c2). In panel c1 the results of the association between IL33
SNPs and eosinophilic asthma in Lifelines is shown, rs992969 as tagSNP of LD block A significantly associated
with this phenotype. Eosinophilic asthma (n=707) vs. healthy controls (n=6,863) (rs992969 [A] OR=1.32,
SE=0.06, P.adj=4.73E-03). In panel c2 the association with all asthma phenotypes lacking eosinophilic asthma
- -
eosinophilic asthma (n=359) vs healthy controls (n=6,863) (rs992969 [A] OR=1.09, SE=0.09, P.adj=0.62). Red
line indicates the cut-off at which the adjusted p-value (FDR) is 0.05. Plots generated using LocusZoom.(38)
Fig 4d- Signal E (tagSNP rs4008366) associates with eosinophilic asthma in Lifelines. In panel d it is shown
that a modest association for signal E exists for eosinophilic asthma. Eosinophilic asthma (n=707) vs. healthy
controls (n=6,863) (rs4008366 [G] OR=1.26, SE=0.070, P.adj=0.045). Red line indicates the cut-off at which the
adjusted p-value (FDR) is 0.05. Plot generated using LocusZoom.(38)
Figure 5- eQTL bronchial brushes in context of eosinophil associated signals
Figure 5- At the IL33 locus, the phenotype association signals for blood eosinophil counts in the general population (n=13,395)
is shown in the upper panel, and the eQTL signals for IL33 expression in bronchial brushes shown in the lower panel (genotyped
SNPs only, n=139 subjects). It becomes clear that the main eosinophil-associated genetic signal A, tagged by rs992969, is also
a strong eQTL in bronchial brushes. The A allele associates with higher levels of IL33 mRNA levels. Statistical details can be
found in table II (phenotype) and table III (eQTL). Plots generated using LocusZoom.(38)
Figure 6: Elevated expression of IL33 affects viability and ROS-capturing, but not barrier formation in
bronchial epithelial cells
Panel 6a: Elevated IL33 mRNA (qPCR) was confirmed in the five engineered donor HBEC which was titrated
to result in a range around 10 times higher levels of IL33 in the overexpression condition; matching the fold
change in IL33 expression that we found in HBECs from asthmatic donors compared to HBECs from healthy
controls (8-10 times higher in asthma HBECs, not shown). Data expressed as fold difference in IL33 mRNA
levels compared to no vector control. N=5 HBEC donors, data points represent mean +/-standard deviation for 2
technical replicates per donor.
Panel 6b: Protein expression of IL33 (red) was confirmed in HBECs transduced with lentivirus expressing
human IL33. Cells were processed for immunofluorescent staining at passage 2, two weeks after the lentiviral
transduction when cells were considered virus-free.
Panel 6c: -
passage 2 cells and compared to empty vector (EV) controls (Kruskall Wallis, followed by MWU posthoc
statistics). Data expressed relative to no vector (NV) control, mean +/- standard deviation of n=5 cell donors.
Panel 6d: Level of reduced glutathione was stained using a commercially available assay (VitaBright-
Chemometec) in passage 2 cells, and HBECs overexpressing IL33 -
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controls (Kruskall Wallis, followed by Wilcoxon posthoc statistics). Data expressed relative to no vector (NV)
control, mean +/- standard deviation of n=5 cell donors.
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Abstract (249):
Background: Asthma is a complex disease with multiple phenotypes that may differ in disease pathobiology and treatment
response. Interleukin 33 (IL33) single nucleotide polymorphisms (SNPs) have been reproducibly associated with asthma. IL33
levels are elevated in sputum, and bronchial biopsies of asthma patients. The functional consequences of IL33 asthma SNPs
remain unknown.
Objective: We studied whether IL33 SNPs associate with asthma-related phenotypes and with IL33 expression in lung or
bronchial epithelium. We investigated the effect of increased IL33 expression on human bronchial epithelial cell (HBEC)
function.
Methods: Association between IL33 and asthma phenotypes (Lifelines/DAG/GASP
cohorts) and between SNPs and expression (lung tissue, bronchial brushes, HBECs) was done using regression modelling.
Lentiviral overexpression was used to study IL33 effects on HBECs.
Results: 161 SNPs spanning the IL33 region associated with one or more asthma phenotypes after correction for multiple
testing. We report one main independent signal tagged by rs992969 associating with blood eosinophil levels, asthma and
eosinophilic asthma. A second, independent signal tagged by rs4008366 presented modest association with eosinophilic
asthma. Neither signal associated with FEV1, FEV1/FVC, atopy, and age of asthma onset. The two IL33 signals are expression
quantitative loci (eQTLs) in bronchial brushes and cultured HBECs, but not in lung tissue. IL33 overexpression in vitro resulted
in reduced viability and ROS-capturing of HBECs, without influencing epithelial cell count, metabolic activity or barrier
function.
Conclusion: We identify IL33 as an epithelial susceptibility gene for eosinophilia and asthma, provide mechanistic insight, and
implicate targeting of the IL33 pathway specifically in eosinophilic asthma.
Key Messages:
- Genetic signals at the IL33 locus predominantly associate with blood eosinophil counts in the general population and
with an eosinophilic asthma phenotype.
- These genetic signals influence IL33 levels in the airway epithelium, with the disease risk allele associating with
elevated IL33 in vivo.
- Elevated IL33 has modest paracrine effects on bronchial epithelial cell function in vitro, implicating that epithelial
derived IL33 may more likely affect other effector cell types such as type 2 immune cells, eosinophils or mast cells.
Capsule Summary (30, max 35 words):
This study identifies IL33 as an epithelial susceptibility gene for eosinophilia and eosinophilic asthma, supporting the IL33
pathway as a likely candidate for targeted treatment strategies specifically in eosinophilic asthma.
Keywords:
asthma phenotypes, IL33 SNPs, eQTL, bronchial epithelium, functional translation
Abbreviations:
AHBEC: Asthma Human Bronchial Epithelial Cell
ALI: Air Liquid Interface
AOO: Age Of Onset
AUC: Area Under the Curve
BEGM: Bronchial Epithelial Growth Medium
BHR: Bronchial Hyper Responsiveness
CMV: CytoMegaloVirus
ECIS: Electric Cell Substrate Impedance Sensing
EUR: European
DAG: Dutch Asthma GWAS
FDR: False Discovery Rate
FeNO: Fraction of exhaled Nitric Oxide
FEV1: Forced Expiratory Volume 1st second
FVC: Forced Vital Capacity
GASP: Genetics of Severe Asthma Phenotypes
GSH: Glutathione
GWAS: Genome Wide Association Study
HBEC: Human Bronchial Epithelial Cell
HDM: House Dust Mite
HWE: Hardy Weinberg Equilibrium
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IgE: Immunoglobulin E
IL1RL1: Interleukin 1 Receptor Like 1




MAF: Minor Allele Frequency
MOI: Multiplicity Of Infection
NGS: Next Generation Sequencing
OR: Odds Ratio
P.adj: Adjusted p-value (FDR)
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Introduction:
Asthma is a common, complex, heterogeneous disease that results from the interaction between genetic
and environmental factors. It is a chronic inflammatory condition of the airways, characterized by bronchial
hyperresponsiveness and reversible airway obstruction. Asthma may consist of several endotypes characterized by
differences in specific phenotypes, underlying pathobiology, and (treatment) outcomes in individual patients(1).
Genome-wide association studies (GWAS) have identified a large number of asthma loci(2-9), including single
nucleotide polymorphisms (SNPs) in Interleukin (IL)33 and the gene encoding its receptor Interleukin 1 Receptor
Like 1 (IL1RL1)(9). Both loci were originally discovered as associated with blood eosinophils in general population
cohorts(10,11). Next to these common SNPs, a rare IL33 loss of function mutation has been shown to reduce blood
eosinophil counts and protect from asthma(12).
IL33 is an alarmin released upon cellular damage from e.g. epithelial cells. Extracellular IL33 induces
signalling via the heterodimeric receptor complex IL1RL1/IL1RAP. Airway IL33 levels have been associated with
type 2 cytokines levels and a positive correlation with eosinophil numbers in asthma patients was recently
reported(13). High IL33 levels have been found in induced sputum and bronchial biopsies of asthma patients
compared to non-asthmatic controls(14-16). Moreover, IL33 may have a paracrine effect on the airway epithelium,
as this epithelium has been shown responsive to IL33(17,18). These data suggest a connection between epithelium-
derived IL33, eosinophilic inflammation and asthma.
Nevertheless, the functional relevance of common asthma-associated SNPs in IL33 remains largely
unknown. Moreover, genetic association studies thus far have focused on asthma diagnosis, while the contribution
of genetic variants to distinct phenotypes of asthma has not been addressed. We hypothesize that genetic variants
at the IL33 locus drive specific phenotypes of asthma by activating a type-2 cytokine dominated immune response,
characterized by eosinophilic lung inflammation. Therefore, this study aimed to investigate 1) whether SNPs in
the IL33 region associate with specific asthma phenotypes; 2) whether these IL33 SNPs form quantitative trait loci
(QTL) for IL33 expression in lung tissue and/or bronchial epithelial samples in vivo and in vitro; and 3) whether
increased IL33 expression alters human bronchial epithelial cell function.
Materials/Methods:
Detailed methods are described in the online supplement.
Codes available on https://git.web.rug.nl/P252222/IL33_Ketelaaretal_JACI2020.
Study design (see also figure 1)
SNPs in the region of IL33 were tested for association with asthma
phenotypes using regression modelling. Briefly, we tested association of the IL33 SNPs in a Dutch general
population cohort (Lifelines(19); n=13,395) with eosinophil counts, FEV1 and FEV1/FVC. From this general
population cohort we subsequently took the asthma subpopulation (n=1, and
investigated genetic association with eosinophil counts, eosinophilic asthma (asthma and blood eosinophils >150
cells/µL, n=707, as this cut-off is a good predictor for airway eosinophilia (>2% sputum eos (20), non-eosinophilic
asthma (asthma and blood eosinophils <150 cells/uL, n=359), FEV1, FEV1/FVC and asthma with airway
obstruction (asthma and FEV1<80% of predicted (n=258) or FEV1/FVC<70% (n=324)). In a meta-analysis of two
independent asthma cohorts of n=2,536 moderate-severe asthma patients (GASP, UK(21))) and n=909 asthma
patients of mild-moderate severity (DAG, the Netherlands(22)), we then evaluated association of IL33 SNPs with
atopy, blood eosinophils, total serum IgE, age of asthma onset, and lung function (FEV1, FEV1/FVC).
We then selected independent genetic signals based on LD (r2<0.1), followed by conditional analyses on the most
significantly associated SNP. Functional investigations of selected independent genetic signals included
expression and protein quantitative loci studies in lung tissue (n=1,111), bronchial brushes (n=139) and primary
asthma derived human bronchial epithelial cells (AHBECs, n=35). Potential function was investigated using
ENCODE, PredictSNP, Meta-SNP, and Polyphen-2 data(23-25). We tested for inducible expression (e)QTL and
protein (p)QTL by exposing AHBECs (n=18) of various IL33 genotypes to asthma-relevant stimuli (HDM, RV16).
Finally, we overexpressed IL33 in (healthy-derived) HBECs (n=5) to investigate effects on cell count, metabolic
activity, viability, ROS-capturing and epithelial barrier.
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Genotype-phenotype analysis
A total of 1,970 imputed SNPs (Lifelines, all overlapping with DAG/GASP) and 2,457 imputed SNPs
(DAG/GASP) were available for the association analyses based on and chromosomal location of
400kb up- and downstream IL33 (Chr9: . This region encompasses all known asthma-
associated SNPs (table I, table S1). Associations of SNPs with asthma phenotypes were performed with PLINK
v1.90b6.7(26) (Lifelines (27) (DAG/GASP) using an additive genetic model. DAG/GASP were
meta-analysed in METAL(28) using a fixed model, (table S2-S3). An adjusted p-value (P.adj)<0.05 (FDR) was
considered statistically significant.
Functional genetics
QTL and ENCODE investigations
We tested for expression quantitative trait loci (eQTL) in lung tissue (n=1,111) and bronchial brushes (n=139)
(table S5) using a linear regression model to investigate the association between SNPs and log-transformed IL33
expression data. We employed an additive genetic model with age, gender, smoking status and the PCs explaining
>1% of expression variance as covariates using R statistics(29). We did not have data on medication use for these
cohorts, so could not correct for this covariate, but the currently used covariates are thought to reflect main
confounders in eQTL analyses (22,30).We also tested for (inducible) QTLs in cultured bronchial epithelial cells
(n=18-35) obtained from bronchial brushes/biopsies from asthma patients as described(31). AHBECs were
stimulated with 50µg/ml house dust mite (HDM) or rhinovirus (RV16, MOI=1) for 24 hours and RNA lysates
collected(32). Cells were genotype-stratified and expression compared using Kruskal-Wallis tests. A p-value<0.05
was considered statistically significant. ENCODE was used to identify potential functional effects of tagSNPs and
SNPs in LD (r2>0.3). SNPs were functionally checked for DNase I hypersensitive sites, histone mark sites, binding
motifs, and regulatory motifs using RegulomeDB, HaploReg, ChromHMM and Segway(23,24).
Functional bronchial epithelial cell studies
In order to investigate the functional consequences of increased IL33 in bronchial epithelial cells, we stably
overexpressed human full-length IL33 (aa1-270) in primary HBECs isolated from 5 healthy individuals (Lonza,
#CC-2540). IL33 mRNA and protein expression was quantified by qPCR and immunofluorescence respectively.
We analysed cell count, viability and metabolic activity, as well as ROS-capturing ability (glutathione assay) and
barrier function (ECIS) in these cultures. We used Kruskal-Wallis for all parameters except for longitudinal area
under the curves (AUCs) comparisons of ECIS data, which were compared using a Z-test. A p-value<0.05 was
considered statistically significant.
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Results:
Genetic association with phenotypes of asthma:
The IL33 locus particularly associates with eosinophilia and eosinophilic asthma
Overall in DAG/GASP and Lifelines (S2-S3), 161 SNPs significantly associated with one or more asthma
phenotypes (P.adj<0.05 (FDR); tables S11-15), mainly derived from the Lifelines cohort. From these, 144 SNPs
comprised five LD blocks (A-E, r2>0.1). Markedly, these five LD blocks all associated with an eosinophilic
phenotype; either with blood eosinophil counts, eosinophilic asthma and/or asthma (table I, tables S11-S17, figure
E2/E3). LD block A shows a significant association with blood eosinophil counts in the general population
(tagSNP rs992969[allele A] beta=0.058+/- SE=0.0089, P.adj=7.09E-08, AF=0.25), whilst three other LD blocks
were modestly associated with this phenotype (block B-D, table I). Block E showed association with eosinophilic
asthma (tagSNP rs4008366 [allele T], OR=1.26+/-SE=0.0704, P.adj=0.045, AF=0.67) only.
Outside these five LD blocks, seven SNPs significantly associated with other phenotypes (age of onset or
FEV1/FVC, table S15) and ten significant SNPs were identified in the case-control analyses of resequencing data;
these were relatively rare (MAF~0.03) and hence were not followed-up functionally. We performed conditional
analyses on the LD blocks associated with eosinophilic phenotypes to determine independent signals. A summary
description of association results can be found in the supplementary section M1.
Conditional and sensitivity analyses show one main genetic signal associated with blood eosinophil counts in the
general population
Four LD blocks (A-D, figure 2) showed association with blood eosinophil counts in the Lifelines general
population. Thereby, block A (tagSNP rs992969) shows the largest effect size and statistical significance (table I);
rs992969 explaining 1.6% (R2 regression model=0.016) of the variance in blood eosinophil counts (corrected for
age/gender). Therefore, we conditioned the association analysis for blood eosinophils on rs992969 to test whether
block A-D are independent signals. Conditioning removed the association of signals B-D with blood eosinophil
counts in the general population (see figure 3 and table II). Signal E was not significantly associated with
eosinophil counts, regardless of conditioning. Sensitivity analysis for the main signal A showed that rs992969 still
associated with eosinophil counts in the general population when removing asthma patients (figure 3a-2)
(n=12,329; rs992969 [allele A] beta=0.055, SE=0.009, R2=0.017, P.adj=1.04E-06) or both asthma/allergic patients
(figure 3a-3) (n=6,227; rs992969 [allele A] beta=0.046, SE=0.012, R2=0.020, P.adj=0.02). These analyses show
the presence of one main genetic signal (A) at the IL33 locus associated with blood eosinophil counts in the general
population, independent of the presence of asthma/allergy phenotypes.
Signal A and E associate with eosinophilic asthma
Signal A, driving the association with blood eosinophil counts in the general population, also showed a significant
association with asthma (rs992969[allele A], OR=1.22, SE=0.05, P.adj=0.03) and with eosinophilic asthma
(rs992969[allele A], OR= 1.32+/-SE=0.0618, P.adj=4.73E-03), (figure 3+4). Signal A contains several SNPs
previously associated with asthma (table I). The genetic effect of this main signal on asthma risk remained of
similar size, even when correcting for blood eosinophil counts (OR[A] from 1.22 (P.adj=0.03) to 1.19 (P.adj=0.08),
figure 4b).
Signal E was the other LD block associated with eosinophilic asthma (tagSNP rs4008366, figure 4d), with a
significantly large effect size. Lack of power precluded conditional analyses for the eosinophilic asthma
phenotype, so (in)dependency of block E could not be confirmed. However, this block represents a genetically
independent signal in other cohorts (table II), underscoring it may be a distinct signal and may represent a distinct
mechanism underlying asthma pathogenesis. Therefore, two signals (A and E) were selected for functional follow-
up.
To assess whether our definition of eosinophilic asthma based on the cut-off for blood eosinophils at 150 cells/uL
impacted on the associations observed, we repeated the analysis at a cut-off of 300 cells/uL as a definition for
eosinophilic asthma. These additional analyses of eosinophilic asthma, including a higher cut-off of eosinophil
counts, identify the same associations with slightly higher effect sizes (see supplemental table S8/S9), but not FDR
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Table II- Conditioning on rs992969 in the association of IL33 with blood eosinophils in the general
population of Lifelines removed signals B-D
Conditional analyses were performed in n=13,395 subjects from the Lifelines general population, studying the
effect of IL33 SNPs on level of blood eosinophils, by taking rs992969 (=lowest p-value SNP associated with
level of blood eos) as covariate in the regression model. These were put into the context of independent SNPs as
determined in other large cohorts. r2= relative to tagSNP of LD block A/B/C/D/E respectively.
* Signal E was not significantly associated with level of blood eosinophils in the general population before
conditional analyses, nor after conditional analyses, but has only been included in this table to show it is in
modest LD with rs343478 (an independent signal in other studies). Because of its association with eosinophilic
asthma, lack of LD with signal A, as well as this LD block also represented an independent signal in multiple
studies, we took this signal forward as an independent phenotype-associated signal in our functional analyses.
**In bold the unconditioned results, in italics the results conditioned on rs992969.
***Adjusted p-value (FDR) statistically significant <0.05.
^ Independent phenotype-associated SNPs at the IL33 locus determined based on conditional analyses in other
large population cohorts: the phenotype studied in the UK Biobank/INTERVAL was blood eosinophil levels in
the general population (n=173,480)(10), in the UK biobank only was asthma (n=41,926 cases vs. n=239,773
controls) (36), whilst the SHARE study examined a combined asthma/allergy phenotype (n=180,129 cases vs
180,709 controls)(37).
Underlined: the two genetic signals taken forward in functional assessment in this study
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QTL/functional investigation of IL33 genetic variation:
After conditional analyses, two independent signals A and E remained for functional follow-up, each with a
tagSNP (rs992969 and rs4008366, table II). These tagSNPs were chosen based on smallest p-value/largest effect
size, largest number of associated phenotypes and if applicable known association with asthma from literature. In
case the tagSNP was not available for functional look-up, a proxySNP at r2>0.5 with the tagSNP of the original
association signal was chosen (table S7).
Signal A and E are IL33 eQTL in bronchial epithelium
To investigate potential functionality of signal A and E, QTL analyses were performed in lung tissue, bronchial
epithelial brushes and cultured bronchial epithelial cells (see table III, S5 and figure 5).
In lung tissue samples, no eQTLs for IL33 were found (table S19 and figure E4). In bronchial brushes, the tagSNP
of signal A was a significant and strong eQTL for IL33, with the disease associated allele correlating with higher
mRNA levels, (rs992969[A] beta=0.331, SD=0.043, P=8.30E-12, AF=0.25). No significant eQTLs were found
for signal E in bronchial brushes. In cultured primary human bronchial epithelial cells (HBECs), the disease
associated allele of signal E (proxy SNP rs442246) associated with lower IL33 mRNA (P=0.029, see table III and
figure E6b). No significant pQTLs were found for IL33 in HBECs for both signal A and E (figure E7).
Signal A and E harbour potential functional elements related to expression regulation of IL33
ENCODE revealed several putative regulatory elements for SNPs in both genetic signals A and E relevant for IL33
transcription (table IIIb). Signal A contained 27 SNPs (LD r2>0.3 with tagSNP) with potential functionality.
Among these is a SNP (rs928413) in strong LD with the phenotype and expression associated tagSNP rs992969
(r2=0.96), forming a CREB1 binding site activating the IL33 promotor. In signal E, 7 SNPs were potential
functional elements, including specific transcription factor binding sites relevant to the regulation of the cellular
oxidative state (e.g. Nrf2) in lung derived cells. Thus, the genetic signals A and E contain likely functional elements
related to expression, forming a potential mechanistic link between phenotype and expression association.
Asthma stimuli induce differential IL33 expression, regardless of genetic background for signal A and E
Next, we tested for the presence of inducible QTLs for IL33 in primary AHBECs after exposure to RV16 (MOI:1)
or house dust mite (HDM, 50µg/mL) and analysed for effects on IL33 mRNA and extracellular protein levels in
an unstratified way or stratified for genetic signals A and E. RV16 induced a decrease in IL33 mRNA levels in
AHBEC (P=0.048), and a marked increase of IL33 protein in the cellular supernatant (P=0.0001). HDM exposure
induced an increase in IL33 RNA and had no significant effects on IL33 protein levels, measured 24h post
stimulation (figure E7). When stratified on signals A and E, no significant differences on the RV16 or HDM
induced effects on IL33 mRNA or protein levels were observed (figures E8/E9).
IL33 overexpression modestly impairs bronchial epithelial cell homeostasis:
In order to investigate the effect of increased IL33 expression, we overexpressed full length IL33 in primary
bronchial epithelial cells using lentiviral delivery (figure E11/E12). We confirmed increased expression of IL33 at
the mRNA level and presence of IL33 protein in engineered cells (figure 5 and figures E13/E14). We found that
overexpression of IL33 does not significantly influence cell number or metabolic activity (figure E15). Viability
was 15-20% lower (P=0.04, figure 5c) and ROS-capturing capacity (presence of free glutathione) was ~20% lower
(P=0.03, figure 5d) in cells that overexpressed IL33 under submerged culture condition. No effect of IL33
overexpression was seen on spreading or formation of an epithelial barrier using ECIS (figure E14).
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Discussion
We set out to determine if SNPs in the IL33 region associate with specific phenotypes of asthma, whether these
regulate IL33 expression in lung tissue or bronchial epithelial samples, and whether increased IL33 expression
alters human bronchial epithelial cell biology. Genetic signals at the IL33 locus predominantly associate with an
eosinophilic phenotype in the general population and asthma subjects, whereby the IL33 risk allele is associated
with higher IL33 expression in vivo. Using conditional analyses we observed one major genetic signal and one
secondary signal. The major signal associates with blood eosinophil counts and (eosinophilic) asthma, while the
secondary signal associates with eosinophilic asthma but not with eosinophil counts in the general population.
Importantly, no association with other asthma-related phenotypes including lung function, atopy, serum IgE levels
and asthma age of onset was observed. Studying the effects of these two genetic signals on IL33 transcription, we
report eQTLs in bronchial brushes and cultured bronchial epithelial cells, but not in lung tissue. Overexpression
of IL33 in bronchial epithelial cells resulted in modest paracrine effect on epithelial cell homeostasis, including
reduction in cell viability and ROS-capturing capacity. With this approach we identify IL33 as an epithelial
susceptibility gene for eosinophilia and asthma, provide mechanistic insight, and support targeting of the IL33
pathway specifically in eosinophilic asthma.
Two genetic IL33 signals associate with eosinophilia in health and disease
The IL33 gene, and the IL1RL1 gene encoding its receptor, have consistently been associated with asthma and
allergy(3-8,21,33-37). Both loci were originally discovered as regions associating with blood eosinophils in the
Icelandic population(11,33), and a strong association with blood eosinophil counts was recently confirmed in a
large general population cohort (n=173,480), combining UK Biobank and INTERVAL studies(10). Also, a rare
loss-of-function IL33 mutation was shown to both reduce eosinophil counts and to protect from asthma(12). These
observations suggest a shared genetic effect of this locus for eosinophilia and asthma. However, it remained
unknown whether these are the same or distinct genetic signals and what additional asthma related phenotypes
these signals may be associated with.
We report five LD blocks that were associated with either blood eosinophil counts and/or eosinophilic
asthma, which after conditional analysis correcting for the strongest signal (rs992969), were reduced to two
independent signals. The fifth signal (E) was not associated with blood eosinophil counts in the general population,
but with eosinophilic asthma. The available subjects (n=707) for the eosinophilic asthma phenotype did not allow
conditional analyses for signal E. However, previous analyses in two very large cohorts (SHARE(37) and UK-
biobank(36) supported the independence of signal E, representing a second signal associated with an eosinophilic
phenotype in our cohorts. This left us with two genetic signals for further study.
We observe a strong association for signal A with both asthma and blood eosinophil counts in our
Lifelines general population cohort, the tagSNP rs992969 explaining 1.6% (R2=0.016) of the variance in
eosinophil counts (corrected for age/gender). SNPs within this signal have previously been reported to associate
with asthma in the UK Biobank, SHARE, and TAGC study, as well as in earlier asthma meta-
analyses(2,4,5,7,21,35-37) and with blood eosinophil counts in the UK biobank/INTERVAL study (rs992969 in
LD r2=0.95 with rs2381416 from UK Biobank/INTERVAL)(10). Using a sensitivity analysis in Lifelines by
removing asthmatic and allergic subjects from the general population, we show that the association with blood
eosinophils remained present with a similar effect size, indicating that the association between this signal A and
blood eosinophils is not fully driven by the presence of asthma or allergy. We find that the association of signal A
with asthma is of similar effect size when correcting for blood eosinophil counts, suggesting that this IL33 genetic
signal- in addition to its effect on blood eosinophil counts- may have an effect on asthma. However, we do find
that the effect of signal A on asthma after correcting for blood eosinophils is no longer FDR significant. (Figure
4.) Therefore, a better powered study is required to conclusively investigate an effect of this signal on asthma
independent from eosinophil counts. Interestingly, we observed an association of signal A with eosinophilic
asthma, but not with non-eosinophilic asthma (figure 4), indicating that patients with this IL33 genetic make-up
would be enriched in the high-eosinophil group. A note of caution is the relatively limited number of subjects in
our non-eosinophilic asthma group (n=359).
An intriguing implication could be that in asthma patients with this particular genetic background (signal A),
treatment targeting the IL33 pathway could have additional effects over treatments targeting eosinophils(42,43).
Notwithstanding, whether the association of IL33 SNPs with asthma and eosinophils are (in)dependent from each
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other remains to be conclusively determined in larger cohorts, allowing causal inference/mediating approaches
like Mendelian randomization(44). Ideally, such an analysis would also take into account IL1RL1 genotypes,
which are likely to interact with IL33 variants on outcomes such as eosinophilic inflammation; as well as a more
direct measure of eosinophilic airway inflammation such as sputum eosinophil counts should be considered.
Functional effects of phenotype-associated IL33 polymorphisms and IL33 expression
Functionally, IL33 signalling has previously been linked to Th2-driven inflammation, contributing to eosinophilic
inflammation(45-47). Moreover, levels of IL33 have been found elevated in induced sputum and bronchial
biopsies of asthma patients compared to non-asthmatic controls(14-16), indicating a dysregulation of IL33
homeostasis in asthma. Therefore, specific genetic variation at the IL33 locus might contribute to eosinophil
numbers and asthma through regulation of IL33 expression levels.
While we did not detect eQTLs for IL33 in lung tissue samples, the tagSNP of signal A was a strong
eQTL for IL33 in bronchial epithelial brushes from healthy subjects (table III, figure 5), with the risk allele
associating with increased IL33 mRNA levels. Signal A harbours a reported IL33 eQTL in a candidate eQTL study
of bronchial biopsies(30), with the same direction of effect. This eQTL signal A also comprised a SNP (rs928413,
in LD r2=0.96 with rs992969) where the phenotype-risk allele was recently found to form a CREB1 binding site,
functionally activating the IL33 promotor in lung epithelial cells(41). This allele associates with higher level of
eosinophils, higher risk of (eosinophilic) asthma and increased IL33 expression in brushes in our cohorts. As lung
tissue resection samples mainly consist of parenchymal lung tissue with minor contributions of airway epithelial
cells, while bronchial brushes contain more than 90% bronchial epithelial cells(48), we interpret these data as
evidence for regulation of IL33 expression in bronchial epithelium.
The bronchial epithelium is the first barrier that the inhaled substances encounter when entering the lung,
and serves to protect the body from potential threats from the environment. The airway epithelium is changed in
asthma patients, with increased susceptibility to and altered repair responses after external damage(49,50), for
example in response to respiratory viruses(51). A GWAS on exacerbation in asthma(2) found the IL33 locus
associated with frequent virus-induced exacerbations in severe childhood-onset asthma, their main IL33 SNP in
strong LD (r2=0.96) with our eosinophilic signal rs992969. Therefore, we tested whether our two phenotype-
associated signals are baseline and/or induced QTLs in cultured bronchial epithelium. Signal E is a modest,
baseline IL33 eQTL, with the eosinophilic risk allele associated with lower IL33 mRNA levels (table III) in these
cells. Although both RV16 and HDM regulated IL33 expression, no effect of the two IL33 signals on the RV16
and HDM induced IL33 response was observed in vitro in our samples. This could indicate that our two signals
may specifically have effects on baseline changes of IL33 expression in epithelium.
The opposite direction of effect in the cultured bronchial epithelial cells compared to the bronchial brushes might
indicate that IL33 gene regulation is different in asthmatic epithelium compared to healthy brushed cells, in
agreement with recent data from Jurak et al. (2018)(52). Alternatively, it could reflect differences in epithelial
cell state with cultured HBECs having a basal cell phenotype(48,53), while bronchial brushes contain mostly
well-differentiated ciliated and secretory epithelial cells(48).
The cell-autonomous effects of increased IL33 expression on cultured HBECs were modest. Nevertheless, the
observed effect of sustained IL33 on reduction of glutathione levels in the epithelium is interesting, as Uchida et
al.(18) showed that the balance between oxidative stress and antioxidant responses plays a key role in controlling
IL33 release from airway epithelium. Our data indicate that the bronchial epithelium is the source of IL33, but
that other cell types should be considered as the main IL33 responsive population, such as tissue-resident
dendritic cells, eosinophils, type 2 innate lymphoid cells, Th2 cells, mast cells and basophils, but also lung
mesenchymal, such as fibroblasts. This is also relevant in the context of steroid-resistant asthma patients. For
example: elevated IL-33 and type 2 cells were still present in corticosteroid resistant pediatric asthma patients,
contributing to airway remodelling via its effects on airway fibroblast.(54,55)
In conclusion, we have reduced the complex IL33 locus into one major and one secondary genetic signal for
eosinophilic asthma. The major IL33 signal risk allele associates with increased IL33 expression levels providing
a putative mechanism. Importantly we have also shown a lack of genetic association of this main genetic signal
with other studied asthma phenotypes. We identified the bronchial epithelial cell as the likely cellular source of
IL33 QTL signals, which is crucial to place the genetic effects on IL33 expression in asthma pathophysiology.
These data need confirmation by e.g. single-cell eQTL analyses in airway wall samples of asthma patients and
healthy controls. This approach might also guide the identification of the main IL33 responding cells.
Nevertheless, our data identifies IL33 as an epithelial susceptibility gene for eosinophilia and asthma, and
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supports the IL33 pathway as a likely candidate for targeted treatment strategies in specifically eosinophilic
asthma, with the potential to affect both eosinophil counts and asthma independently.
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Figure 1: Overview of the flow of the analyses
In above figure the flow of analysis of the current paper is shown. In the first phase, SNPs in a candidate region (400kb+/-
IL33) were associated with asthma phenotypes in Lifelines (n=13,395) and GASP/DAG cohorts (1), including blood
eosinophils, blood neutrophils, FEV1, FEV1/FVC, atopy, blood IgE and age of asthma onset. A total of 161 SNPs
(MAF>0.01) were associated with one or more of these phenotypes; the majority of these associations were found in the
Lifelines general population cohort. A total of 5 independent LD blocks (r2>0.1) were identified (2a). Conditional analyses
on the most significantly associated SNP revealed 2 independent signals left for functional study in QTL cohorts (2b). eQTLs
were studied in lung tissue (n=1,111) and bronchial brushes (n=139), eQTL and pQTL in cultured primary human bronchial
epithelial cells (HBECS, n=35 (3)). Then, functional elements in the phenotype-associated genetic signals were investigated
using ENCODE, PredictSNP, Meta-SNP, Polyphen-2 data (4). Further functional study was done by exposing HBECs (n=18)
to asthma-relevant stimuli (HDM, RV16), investigating inducible eQTL and pQTL; as well as investigating the functional
effects of elevated IL33 (n=5) in vitro, including cell count, metabolic activity, viability, ROS-capturing and resistance (5).
Figure 2- The LD pattern of the five LD blocks (r2>0.1) with phenotype association
The panel shows the LD pattern of the 5 LD blocks/signals (r2>0.1) from the 144 SNPs significantly (FDR<0.05) associated
with asthma features in the Lifelines general population, Lifelines asthma population and DAG/GASP asthma population.
Signal A and E were taken forward in functional assesment in this study. Image generated using the EUR population of the
Phase I cohort of the 1000 genomes study via the online software tool LDlink 3.0, available at:
https://analysistools.nci.nih.gov/LDlink/?tab=home.
Figure 3- Conditioning on the main genetic eosinophilic signal A (rs992969) removes three other signals
(B,C,D) associated with blood eosinophils in the general population of Lifelines.
In figure 3 the association between IL33 region SNPs and level of blood eosinophils in the general population is
shown. Four LD blocks (r2>0.1) could be distinguished for this phenotype (LD block A-D), with LD Block A
representing a strong signal, and block B-D a modest signal. Indeed, conditioning on the tagSNP of LD block A
(rs992969) removed signals B-D. Conditional analyses were performed in n=13,395 subjects from the Lifelines
general population, studying the effect of IL33 SNPs on level of blood eosinophils, by taking rs992969 (=lowest
p-value SNP associated with level of blood eos) as covariate in the regression model. Statistical details can be
found in table II. Red line indicates the cut-off at which the adjusted p-value (FDR) is 0.05. Plots generated
using LocusZoom.(38)
Figure 4- The main genetic IL33 signal (signal A) selected for functional follow-up associates with level of
blood eosinophils (a), asthma diagnosis (b) and eosinophilic asthma (c), whilst signal E associates with
eosinophilic asthma (d)
Fig 4a- Signal A (tagSNP rs992969) associates with level of blood eosinophils in the general population of
Lifelines (a1), independent of the presence of asthma/allergy (a2 and a3). In panel a1 the results of the
association between IL33 SNPs and blood eosinophil levels in the total general population (n=13,395) of
Lifelines are shown, the reference SNP (purple) indicating the tagSNP of LD block A: rs992969, which was
significantly associated with blood eosinophil (beta [A allele]= 0.058, SE=0.009, P.adj=7.09E-08). In panel a2
this association was performed in the general population lacking asthma (n=1,066 asthma patients removed),
rs992969 (purple) still associating with blood eosinophil levels at similar effect size (n=12,329; rs992969 [A]
beta=0.055, SE=0.009, P.adj=1.04E-06). In panel a3 individuals with asthma and allergies (n=6,227
asthma/allergic subjects) were removed, and also then rs992969 (purple dot) associated with blood eosinophil
levels at similar effect size (n=7,168; rs992969 [A] beta=0.046, SE=0.012, P.adj=0.02). Red line indicates the
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cut-off at which the adjusted p-value (FDR) is 0.05. Asthma was defined as self-reported doctor-diagnosed
asthma. Allergy was defined based on at least one self-reported allergy, including eczema, rhinitis, food allergy,
dust allergy, animal allergy, pollen allergy, medication allergy, contact allergy, and insect bite allergy. Plots
generated using LocusZoom.(38)
Fig 4b- Signal A (tagSNP rs992969) associates with asthma diagnosis (Lifelines). Here the association
between IL33 locus SNPs and all asthma is shown, with panel b1 showing the association model corrected for
age and gender, whilst in panel b2 the model in addition was corrected for level of blood eosinophils. b1- All
asthma, uncorrected for blood eosinophils; asthma patients (n=1,066) vs healthy controls (n=6,863) (rs992969
[A], OR= 1.22, SE= 0.05, P.adj=0.03); b2- All asthma, corrected for blood eosinophils; asthma patients
(n=1,066) vs healthy controls (n=6,863) (rs992969 [A], OR=1.19, SE= 0.05, P.adj=0.08). Red line indicates the
cut-off at which the adjusted p-value (FDR) is 0.05. Plots generated using LocusZoom.(38)
Fig 4c- Signal A (tagSNP rs992969) also associates with eosinophilic asthma in Lifelines (c1), but this
signal is not present in non-eosinophilic asthma (c2). In panel c1 the results of the association between IL33
SNPs and eosinophilic asthma in Lifelines is shown, rs992969 as tagSNP of LD block A significantly associated
with this phenotype. Eosinophilic asthma (n=707) vs. healthy controls (n=6,863) (rs992969 [A] OR=1.32,
SE=0.06, P.adj=4.73E-03). In panel c2 the association with all asthma phenotypes lacking eosinophilic asthma
- -
eosinophilic asthma (n=359) vs healthy controls (n=6,863) (rs992969 [A] OR=1.09, SE=0.09, P.adj=0.62). Red
line indicates the cut-off at which the adjusted p-value (FDR) is 0.05. Plots generated using LocusZoom.(38)
Fig 4d- Signal E (tagSNP rs4008366) associates with eosinophilic asthma in Lifelines. In panel d it is shown
that a modest association for signal E exists for eosinophilic asthma. Eosinophilic asthma (n=707) vs. healthy
controls (n=6,863) (rs4008366 [G] OR=1.26, SE=0.070, P.adj=0.045). Red line indicates the cut-off at which the
adjusted p-value (FDR) is 0.05. Plot generated using LocusZoom.(38)
Figure 5- eQTL bronchial brushes in context of eosinophil associated signals
Figure 5- At the IL33 locus, the phenotype association signals for blood eosinophil counts in the general population (n=13,395)
is shown in the upper panel, and the eQTL signals for IL33 expression in bronchial brushes shown in the lower panel (genotyped
SNPs only, n=139 subjects). It becomes clear that the main eosinophil-associated genetic signal A, tagged by rs992969, is also
a strong eQTL in bronchial brushes. The A allele associates with higher levels of IL33 mRNA levels. Statistical details can be
found in table II (phenotype) and table III (eQTL). Plots generated using LocusZoom.(38)
Figure 6: Elevated expression of IL33 affects viability and ROS-capturing, but not barrier formation in
bronchial epithelial cells
Panel 6a: Elevated IL33 mRNA (qPCR) was confirmed in the five engineered donor HBEC which was titrated
to result in a range around 10 times higher levels of IL33 in the overexpression condition; matching the fold
change in IL33 expression that we found in HBECs from asthmatic donors compared to HBECs from healthy
controls (8-10 times higher in asthma HBECs, not shown). Data expressed as fold difference in IL33 mRNA
levels compared to no vector control. N=5 HBEC donors, data points represent mean +/-standard deviation for 2
technical replicates per donor.
Panel 6b: Protein expression of IL33 (red) was confirmed in HBECs transduced with lentivirus expressing
human IL33. Cells were processed for immunofluorescent staining at passage 2, two weeks after the lentiviral
transduction when cells were considered virus-free.
Panel 6c: - g in
passage 2 cells and compared to empty vector (EV) controls (Kruskall Wallis, followed by MWU posthoc
statistics). Data expressed relative to no vector (NV) control, mean +/- standard deviation of n=5 cell donors.
Panel 6d: Level of reduced glutathione was stained using a commercially available assay (VitaBright-
Chemometec) in passage 2 cells, and HBECs overexpressing IL33 -
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controls (Kruskall Wallis, followed by Wilcoxon posthoc statistics). Data expressed relative to no vector (NV)




















The table shows the results of the association analyses of all eosinophilic phenotypes in each cohort for the 5 LD
blocks/signals (r2>0.1). Eosinophilic asthma was defined as asthma with blood eosinophil count >150cells/uL.
Underlined: the two genetic signals taken forward in functional assesment in this study. AF=frequency (EUR
1000G); Alt allele=alternative allele; B=beta; eos=eosinophils/eosinophilic; FDR=false discovery rate value at
alpha 0.05; GWAS= genomewide association study; GenPop =general population; HC=healthy control; kb= kilo
basepairs; Lit.=literature; OR=odds ratio; P.adj= FDR adjusted p-value; Pheno risk allele=phenotype associated
allele; Ref=Reference; SE=standard error.
The table shows the results of the association between the 5 main LD blocks and eosinophilic asthma using two
definitions (>150cells/uL(*n=707) and >300cells/uL(**n=260)) in Lifelines. Underlined: the two genetic signals
taken forward in functional assesment in this study. AF=frequency (EUR 1000G); Alt allele=alternative allele;
B=beta; eos=eosinophils/eosinophilic; FDR=false discovery rate value at alpha 0.05; GWAS= genomewide
association study; GenPop =general population; HC=healthy control; kb= kilo basepairs; Lit.=literature;
OR=odds ratio; P.adj= FDR adjusted p-value; Pheno risk allele=phenotype associated allele; Ref=Reference;
SE=standard error.
The table shows the results of the association between the 5 main LD blocks and eosinophilic asthma using two
definitions (>150cells/uL(*n=1,002) and >300cells/uL(**n=493)) in DAG/GASP. Underlined: the two genetic
signals taken forward in functional assesment in this study. AF=frequency (EUR 1000G); Alt allele=alternative
allele; B=beta; eos=eosinophils/eosinophilic; FDR=false discovery rate value at alpha 0.05; GWAS= genomewide
association study; GenPop =general population; HC=healthy control; kb= kilo basepairs; Lit.=literature;
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B=beta; eos=eosinophils/eosinophilic; FDR=false discovery rate value at alpha 0.05; GWAS= genomewide
association study; GenPop =general population; HC=healthy control; kb= kilo basepairs; Lit.=literature;
OR=odds ratio; P.adj= FDR adjusted p-value; Pheno risk allele=phenotype associated allele; Ref=Reference;
SE=standard error.
The table shows the results of the association between the 5 main LD blocks and eosinophilic asthma using two
definitions (>150cells/uL(*n=1,002) and >300cells/uL(**n=493)) in DAG/GASP. Underlined: the two genetic
signals taken forward in functional assesment in this study. AF=frequency (EUR 1000G); Alt allele=alternative
allele; B=beta; eos=eosinophils/eosinophilic; FDR=false discovery rate value at alpha 0.05; GWAS= genomewide
association study; GenPop =general population; HC=healthy control; kb= kilo basepairs; Lit.=literature;
OR=odds ratio; P.adj= FDR adjusted p-value; Pheno risk allele=phenotype associated allele; Ref=Reference;
SE=standard error.






















